A lthough the names of Bourneville and Pringle are associated with the disease they were not the first who reported patients with signs later defined as the diagnostic criteria. Reports start in the 19th century and are based on descriptions of clinical and pathological findings.
The characteristic skin lesions were mentioned for the first time in 1835. Rayer's atlas on skin diseases illustrates the facial ''végétations vasculaires''. These lesions were renamed adenoma sebaceum by Pringle, who is remembered today for his description of a patient with adenoma sebaceum. 1 He also mentioned the associated mental subnormality.
In 1862 Von Recklinghausen, primarily associated with neurofibromatosis, first mentioned the cerebral involvement. On autopsy of a newborn that died a few minutes after birth, he found cardiac myomata and sclerotic brain lesions, but he did not make the association between the two pathologies. Description of the cerebral pathology and neurological signs is credited, however, to Bourneville. He proposed the term sclérose tubéreuse des circonvolutions cérébrales to characterise the large islets of sclerosis he found in the cortical gyri of two patients who died of epilepsy. 2 3 He found kidney masses in one of the patients as well.
It was in the beginning of the 20th century that a more complete clinical picture of tuberous sclerosis complex (TSC) was obtained. The association between the cerebral, renal, cardiac, and dermal lesions was first recognised in 1905, leading to the clinical diagnostic triad consisting of epilepsy, idiocy, and adenoma sebaceum, often called after Vogt. Van der Hoeve, who characterised the retinal hamartomas, introduced the name phakomatosis (phakos means spot), comprising both TSC and neurofibromatosis. After the first descriptions of radiological calcifications, the introduction of the CT and MRI scans greatly improved the diagnostic process. Gomez, the ''godfather of TSC research'', first published the full clinical and subclinical spectrum of TSC in 1979. 4 The hereditary basis of TSC was mentioned as early as 1913. Positional cloning studies led to the identification of TSC1 with the locus on chromosome 9, and TSC2 with the locus on chromosome 16. Better insight in the putative molecular mechanisms underlying the development of the hamartomatous lesions has yet to be achieved. 
